Latest edition of the Journal of Neuromuscular Diseases now online – Sep 2020

A new issue of the Journal of Neuromuscular Diseases has recently been released. Read it below:

Journal of Neuromuscular Diseases: Volume 7, issue 4

*NMD4C lead investigator Hanns Lochmüller is joint editor-in-chief of the Journal of Neuromuscular Diseases, together with Carsten Bönnemann of the NIH National Institute of Neurological Disorders and Stroke.

 

Articles in this issue:

  • Towards central nervous system involvement in adults with hereditary myopathies
  • Induction of skeletal muscle progenitors and stem cells from human induced pluripotent stem cells
  • Lower extremity muscle involvement in the intermediate and Bethlem myopathy forms of COL6-related dystrophy and Duchenne muscular dystrophy: A cross-sectional study
  • Ganglionopathies associated with MERRF syndrome: An original report
  • Respiratory dysfunction in Becker muscular dystrophy patients: A case series and autopsy report
  • Decision-making and selection bias in four observational studies on Duchenne and Becker muscular dystrophy
  • Phenotypic spectrum of myopathies with recessive anoctamin-5 mutations
  • Natural history of type 1 spinal muscular atrophy in a series of Argentinian children
  • Neuroanatomical models of muscle strength and relationship to ambulatory function in spinal muscular atrophy
  • Facilitators and barriers to wearing hand orthoses by adults with Duchenne muscular dystrophy: A mixed methods study design
  • Identification and characterization of splicing defects by single-molecule real-time sequencing technology (PacBio)
  • Swallowing, chewing, and speaking: Frequently impaired in oculopharyngeal muscular dystrophy
  • Correlation between quantitative MRI and muscle histopathology in muscle biopsies from healthy controls and patients with IBM, FSHD, and OPMD
  • A new point mutation in the PMP22 gene in a family suffering from atypical HNPP
  • Severe inflammatory myopathy in a pulmonary carcinoma patient treated with Pembrolizumab: An alert for myologists
  • Familial oculo-leptomeningeal transthyretin amyloidosis caused by Leu55Arg mutation
  • Taking a Strohl through history: Putting Strohl back in Guillain-Barré-Strohl syndrome
  • Measuring outcomes in adults with spinal muscular atrophy: Challenges and future directions – Meeting report
JND-cover

Read next...

Hope On The Horizon: Trials Treatments and Therapies for DMD, DM1 and MG

Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG

Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!

Website - 2026 NMD4C Awards Now Open

2026 Awards Now Open for Nominations!

We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.

AGAMREE (vamorolone) Approved treatment for DMD in Canada

A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada

Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.